Aspira Women’s Health Inc. to Report Third Quarter 2021 Financial Results on November 10

Rhea-AI Summary

Aspira Women’s Health, Inc. (Nasdaq: AWH) will report its third-quarter financial results for the period ending September 30, 2021, on November 10, 2021, before the market opens. Following the release, an investor conference call and webcast will be held at 8:30 a.m. ET. The company focuses on innovative testing options for women’s health, particularly in ovarian cancer risk assessment and pelvic diseases. Its products include OVA1® and OVERA® for ovarian malignancy detection, with ongoing research into new testing solutions like OVANEX™ and EndoCheck™.

Positive

• Upcoming financial results announcement may indicate business growth or improvements.
• Focus on innovative testing solutions addresses significant health concerns for women.

Negative

• None.

AUSTIN, Texas, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that it will report financial results for the third quarter ended September 30, 2021 on Wednesday, November 10, 2021, before the market open, followed by an investor conference call and webcast at 8:30 a.m. Eastern Time.

Wednesday, November 10 at 8:30 am ET
Domestic:	877-407-4018
International:	201-689-8471
Conference ID:	13724440
Webcast:	https://78449.themediaframe.com/dataconf/productusers/vvdb/mediaframe/47156/indexl.html

About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women’s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1® plus includes our FDA-cleared products, OVA1® and OVERA®, to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiX^TM testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women’s Health is delivering a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development are OVANEX^TM and EndoCheck^TM. Visit our website for more information at www.aspirawh.com.

Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel: 617-430-7577
arr@lifesciadvisors.com

FAQ

When will Aspira Women’s Health report its Q3 2021 financial results?

Aspira Women’s Health will report its Q3 2021 financial results on November 10, 2021.

What time will the Aspira Women’s Health investor conference call take place?

The investor conference call for Aspira Women’s Health will take place at 8:30 a.m. ET on November 10, 2021.

What is the focus of Aspira Women’s Health Inc.?

Aspira Women’s Health focuses on innovative testing options for women’s health, particularly in ovarian cancer risk assessment and pelvic diseases.